KVP Capital Advisors
Latest statistics and disclosures from KVP Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, WHWK, ERAS, TRVI, STRO, and represent 35.13% of KVP Capital Advisors's stock portfolio.
- Added to shares of these 8 stocks: TNDM, AVBP, DSGN, MLYS, ERAS, ARTV, EOLS, CMPX.
- Started 6 new stock positions in MLYS, TNDM, EOLS, DSGN, AVBP, ARTV.
- Reduced shares in these 5 stocks: TERN (-$23M), AXSM (-$5.9M), RVMD, TVTX, Soleno Therapeutics.
- Sold out of its positions in RVMD, Soleno Therapeutics, TERN.
- KVP Capital Advisors was a net seller of stock by $-19M.
- KVP Capital Advisors has $136M in assets under management (AUM), dropping by 1.75%.
- Central Index Key (CIK): 0001858198
Tip: Access up to 7 years of quarterly data
Positions held by KVP Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for KVP Capital Advisors
KVP Capital Advisors holds 35 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 10.5 | $14M | 43k | 334.79 |
|
|
| Aadi Bioscience (WHWK) | 7.3 | $9.9M | 2.2M | 4.58 |
|
|
| Erasca (ERAS) | 6.1 | $8.3M | +33% | 455k | 18.32 |
|
| Trevi Therapeutics (TRVI) | 5.7 | $7.7M | 414k | 18.65 |
|
|
| Sutro Biopharma Com Shs (STRO) | 5.5 | $7.5M | 227k | 33.20 |
|
|
| Tango Therapeutics (TNGX) | 5.3 | $7.2M | 230k | 31.26 |
|
|
| Mbx Biosciences (MBX) | 4.9 | $6.7M | 122k | 55.20 |
|
|
| Protagonist Therapeutics (PTGX) | 4.8 | $6.5M | 53k | 122.58 |
|
|
| Edgewise Therapeutics (EWTX) | 4.0 | $5.4M | 133k | 40.63 |
|
|
| Tandem Diabetes Care Com New (TNDM) | 3.3 | $4.5M | NEW | 301k | 15.09 |
|
| Disc Medicine (IRON) | 3.1 | $4.3M | 58k | 73.14 |
|
|
| Savara (SVRA) | 2.7 | $3.7M | 605k | 6.16 |
|
|
| Arrivent Biopharma (AVBP) | 2.6 | $3.5M | NEW | 102k | 34.74 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $3.0M | 29k | 106.62 |
|
|
| Achieve Life Sciences (ACHV) | 2.2 | $3.0M | 462k | 6.53 |
|
|
| Ideaya Biosciences (IDYA) | 2.2 | $3.0M | 80k | 37.27 |
|
|
| Ocular Therapeutix (OCUL) | 2.2 | $2.9M | 300k | 9.82 |
|
|
| Axsome Therapeutics (AXSM) | 2.2 | $2.9M | -66% | 12k | 244.77 |
|
| Design Therapeutics (DSGN) | 2.0 | $2.7M | NEW | 185k | 14.47 |
|
| United Therapeutics Corporation (UTHR) | 1.9 | $2.6M | 4.8k | 541.83 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 1.8 | $2.5M | 45k | 55.00 |
|
|
| Immix Biopharma (IMMX) | 1.7 | $2.4M | 230k | 10.31 |
|
|
| Miragen Therapeutics (VRDN) | 1.7 | $2.3M | 125k | 18.37 |
|
|
| Mineralys Therapeutics (MLYS) | 1.7 | $2.3M | NEW | 84k | 26.98 |
|
| Bright Minds Biosciences Com New (DRUG) | 1.6 | $2.2M | 32k | 70.20 |
|
|
| Travere Therapeutics (TVTX) | 1.6 | $2.2M | -57% | 39k | 56.81 |
|
| Zura Bio Class A Ord Shs (ZURA) | 1.6 | $2.2M | 373k | 5.90 |
|
|
| Artiva Biotherapeutics (ARTV) | 1.4 | $1.9M | NEW | 200k | 9.70 |
|
| Nektar Therapeutics Com New (NKTR) | 1.4 | $1.9M | 27k | 69.81 |
|
|
| Compass Therapeutics (CMPX) | 1.2 | $1.7M | +54% | 771k | 2.19 |
|
| Cabaletta Bio (CABA) | 1.2 | $1.6M | 505k | 3.11 |
|
|
| Vera Therapeutics Cl A (VERA) | 1.0 | $1.4M | 33k | 42.91 |
|
|
| Evolus (EOLS) | 0.8 | $1.0M | NEW | 150k | 6.94 |
|
| Celcuity (CELC) | 0.3 | $419k | 4.0k | 104.62 |
|
|
| Vyne Therapeutics (VYNE) | 0.2 | $326k | 501k | 0.65 |
|
Past Filings by KVP Capital Advisors
SEC 13F filings are viewable for KVP Capital Advisors going back to 2025
- KVP Capital Advisors 2026 Q2 filed Aug. 13, 2026
- KVP Capital Advisors 2026 Q1 filed May 13, 2026
- KVP Capital Advisors 2025 Q4 filed Feb. 18, 2026